Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 257-077-0 | CAS number: 51240-95-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
In the EOGRTS (OECD 443), oral (gavage) administration of 1,1,3,3 -tetramethylbutyl peroxyneodecanoate resulted in treatment-related effects on sperm motility and morphology in both F0 and F1 male rats at 450 mg/kg bw/day. Mean percentages of motile sperm and progressive sperm were markedly decreased. Motile and progressive sperm were absent in samples from a few males, and no progressive sperm was found in samples of some other males. In addition, mean numbers of cells with a detached head or with an abnormal neck had increased. In addition, a reduced fertility index was observed at 450 mg/kg bw/day. No such changes were seen at 50 or 150 mg/kg bw/day. A NOAEL of 150 mg/kg bw/day for sperm findings was also noted in an oral OECD 421 study with 10-wk pre-mating exposure of the males. Oral (gavage) administration at a dose level of 300 mg/kg bw/day for 90 days also resulted in findings in sperm concentration and motility and an associated increase in sperm abnormalities. After a 28-day observation period, these findings were not reversible in males treated at 300 mg/kg bw/day. The next lower level of 100 mg/kg bw/day was established as No Observed Adverse Effect Level (NOAEL) in males. Based on these studies with at least 90-day exposure of males, an overall NOAEL of 150 mg/kg bw/day was established for male reproductive toxicity.
In both the EOGRTS and OECD 421 study, female fertility was considered unaffected by treatment up to and including the high dose tested; the NOAEL for female reproductive toxicity therefore was at least 450 mg/kg bw/day.
The NOAEL for developmental toxicity in the EOGRTS was at least 450 mg/kg bw/day.
In the EOGRTS but not in the 90-day study, microscopic heart findings were noted in both male and female F0 and F1 rats with a NOAEL of ca. 50 mg/kg bw/day.
In all these studies of at least 90 day duration, dose-related kidney changes were noted in males which were considered related to alpha-2u-globulin nephropathy, a male-rat-specific syndrome with no relevance to man.
Effect on fertility: via oral route
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 150 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- K1 GLP study. NOAEL for females is at least 450 mg/kg/day.
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Effects on developmental toxicity
Description of key information
The oral administration of 1,1,3,3-tetramethylbutyl peroxyneodecanoate to pregnant rats by gavage during gestation days 5 -19, at dose levels of 0, 30, 175 or 1000 mg/kg bw/day resulted in a clear adverse effect on body weight gain and food consumption at the high dose level. Although some improvement was evident, cumulative body weight gains for females treated with 1000 mg/kg bw/day remained lower than controls throughout the dosing period with body weight gain adjusted for the contribution of gravid uterus also being markedly lower than controls. Taking into consideration the overall results, the NOAEL for the pregnant female rat was considered to be 175 mg/kg bw/day.
At 1000 mg/kg bw/day, fetal and litter weights were marginally lower than in controls with skeletal examination identifying a number of treatment-related variants. These observations were, however, considered to be due to maternal toxicity which resulted in slight reduction in fetal growth rather than an indication of a direct effect of the test item on fetal growth and development. The NOAEL for developmental toxicity was therefore considered to be 175 mg/kg/day, the limited findings noted at 1000 mg/kg bw/day were observed in the presence of clear maternal toxicity.
In the OECD 421 study the developmental NOAEL was established at 150 mg/kg bw/day based on a slightly lower mean body weight in pups of both sexes of the 450 mg/kg bw/day group compared to controls at PND13.
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 175 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- GLP, Klimisch 1 study.
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
In male rats, reduced sperm concentration and motility were observed associated with an increase in sperm morphological abnormalities. These findings were noted at 450 mg/kg bw/day in an EOGRTS (OECD 443) and in an OECD 421 study with 10-wk premating, and at 300 mg/kg bw/day in the 90-day study (OECD 408; see section 7.5). In addition, a reduced fertility index was observed in the EOGRTS at 450 mg/kg bw/day. Based on these results the substance is classified as toxic to reproduction category 1B (H360F). No classification is needed for developmental toxicity as the only findings noted were a lower fetal body weight and a number of skeletal variations which were seen in the presence of clear maternal toxicity at a high dose of 1000 mg/kg bw/day.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.